Shares of Clearmind Medicine Inc. (CMND) surged over 70% on Monday morning after reporting encouraging clinical data.
The stock is currently trading at $1.23, up $0.51 or 70.02%, on the Nasdaq. It opened at $1.33 after closing the previous session at $0.72. The stock has traded between $0.59 and $52.40 over the past 52 weeks.
Clearmind said its CMND-100 drug candidate met the primary safety endpoint in a Phase I/IIa trial for Alcohol Use Disorder (AUD).
The treatment showed strong tolerability with no serious adverse events, supporting further development.
The results boost confidence in its non-hallucinogenic psychedelic-based therapy pipeline.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.